Institutional Ownership
Bridgebio Pharma Inc
CUSIP 10806X102COMBBIOQ1 2026
13D / 13G Filings
45
Schedule 13D/13G on record
Beneficial Filers
14
Distinct reporting persons
Largest Stake
36.4%
Max % of class reported
Institutional Holders
449
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
45 filings · latest Feb 17, 2026
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Feb 17, 2026 | Janus Henderson Group PLC | 13G | 5.7% | 11.00M | SEC |
| 2 | Feb 17, 2026 | Viking Global Investors LP | 13D/A | 6.8% | — | SEC |
| 3 | Nov 14, 2025 | Viking Global Investors LP | 13D/A | 8.2% | — | SEC |
| 4 | Aug 14, 2025 | Viking Global Investors LP | 13D/A | 9.7% | — | SEC |
| 5 | Jul 29, 2025 | The Vanguard Group | 13G/A | 8.7% | 16.48M | SEC |
| 6 | Jul 1, 2025 | Viking Global Investors LP | 13D/A | 9.8% | — | SEC |
| 7 | May 14, 2025 | Kkr Genetic Disorder L.P. | 13D/A | 7.0% | — | SEC |
| 8 | Mar 12, 2025 | Viking Global Investors LP | 13D/A | 11.7% | — | SEC |
| 9 | Mar 7, 2025 | Kkr Genetic Disorder L.P. | 13D/A | 10.1% | — | SEC |
| 10 | Feb 13, 2025 | Neil Kumar | 13G/A | 5.4% | 10.47M | SEC |
35 more beneficial-ownership filings on Premium
See the full Schedule 13D/13G history for Bridgebio Pharma Inc.
Unlock full historyTop Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Blackrock, Inc. | 14.21M | $1.06B |
| 2 | Kohlberg Kravis Roberts & Co. L.P. | 13.26M | $984.76M |
| 3 | Janus Henderson Group PLC | 13.18M | $978.61M |
| 4 | Viking Global Investors LP | 11.84M | $879.42M |
| 5 | Farallon Capital Management LLC | 9.37M | $695.48M |
| 6 | Aisling Capital Management LP | 5.09M | $377.95M |
| 7 | Geode Capital Management, LLC | 4.92M | $371.93M |
| 8 | State Street Corp | 4.93M | $366.42M |
| 9 | Invesco Ltd. | 4.59M | $341.06M |
| 10 | Frazier Life Sciences Management, L.P. | 3.45M | $256.06M |